Effect of Frail Phenotype on Cardiorenal Risk and Healthcare Utilization in Older Patients with Chronic Kidney Disease.

IF 2.4 4区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiorenal Medicine Pub Date : 2024-01-01 Epub Date: 2024-10-07 DOI:10.1159/000541807
Chien-Yao Sun, Chia-Ter Chao, Shang-Han Wu, Jia-Ling Wu, Tsai-Chieh Ling, Deng-Chi Yang, Wei-Ren Lin, Chieh-Hsin Huang, Yu-Tzu Chang
{"title":"Effect of Frail Phenotype on Cardiorenal Risk and Healthcare Utilization in Older Patients with Chronic Kidney Disease.","authors":"Chien-Yao Sun, Chia-Ter Chao, Shang-Han Wu, Jia-Ling Wu, Tsai-Chieh Ling, Deng-Chi Yang, Wei-Ren Lin, Chieh-Hsin Huang, Yu-Tzu Chang","doi":"10.1159/000541807","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Limited data have addressed frailty's role in cardiorenal risk among older adult patients with chronic kidney disease (CKD). We investigated whether frailty could predict major renal and cardiovascular events, healthcare utilization, and mortality in these patients.</p><p><strong>Methods: </strong>We conducted a prospective cohort enrolling patients aged ≥75 years with a stable estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. The frailty phenotype consists of shrinking, low activity, exhaustion, weakness, and slowness, scored 0 to 5. The primary composite renal outcome was a ≥25% decrease in eGFR concurrent with CKD stage progression or dialysis initiation. Secondary outcomes included major adverse cardiovascular events (MACE), emergency room (ER) visits, all-cause mortality, and hospitalization. Using multivariate Cox models with/without competing risk analyses, we explored frailty's impact on these outcomes.</p><p><strong>Results: </strong>Among 203 older CKD patients (mean age: 81.6 ± 5.0 years, female: 40.9%, diabetes: 33.0%, body mass index: 24.9 ± 3.7 kg/m2), 67.9% were frail. Over 3.47 years, 38.9% faced composite renal outcomes; 13.3%, MACE; 15.3%, mortality; and more than half utilized healthcare. Every one-point frailty elevated renal outcome risk by 28.0% (HR: 1.28, 95% confidence interval [CI]: 1.03-1.59) and significantly increased secondary outcomes (MACE [HR: 1.43, 95% CI: 0.99-2.08], hospitalization [HR: 1.24, 95% CI: 1.06-1.46], unexpected ER visit [HR: 1.20, 95% CI: 1.03-1.39], and mortality [HR: 1.51, 95% CI: 1.06-2.16]). Results were consistent across subgroups and competing risk analysis.</p><p><strong>Conclusion: </strong>In CKD patients aged ≥75 years, frailty was associated with progressive kidney disease, increased mortality, and healthcare utilization.</p>","PeriodicalId":9584,"journal":{"name":"Cardiorenal Medicine","volume":" ","pages":"600-611"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiorenal Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000541807","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Limited data have addressed frailty's role in cardiorenal risk among older adult patients with chronic kidney disease (CKD). We investigated whether frailty could predict major renal and cardiovascular events, healthcare utilization, and mortality in these patients.

Methods: We conducted a prospective cohort enrolling patients aged ≥75 years with a stable estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2. The frailty phenotype consists of shrinking, low activity, exhaustion, weakness, and slowness, scored 0 to 5. The primary composite renal outcome was a ≥25% decrease in eGFR concurrent with CKD stage progression or dialysis initiation. Secondary outcomes included major adverse cardiovascular events (MACE), emergency room (ER) visits, all-cause mortality, and hospitalization. Using multivariate Cox models with/without competing risk analyses, we explored frailty's impact on these outcomes.

Results: Among 203 older CKD patients (mean age: 81.6 ± 5.0 years, female: 40.9%, diabetes: 33.0%, body mass index: 24.9 ± 3.7 kg/m2), 67.9% were frail. Over 3.47 years, 38.9% faced composite renal outcomes; 13.3%, MACE; 15.3%, mortality; and more than half utilized healthcare. Every one-point frailty elevated renal outcome risk by 28.0% (HR: 1.28, 95% confidence interval [CI]: 1.03-1.59) and significantly increased secondary outcomes (MACE [HR: 1.43, 95% CI: 0.99-2.08], hospitalization [HR: 1.24, 95% CI: 1.06-1.46], unexpected ER visit [HR: 1.20, 95% CI: 1.03-1.39], and mortality [HR: 1.51, 95% CI: 1.06-2.16]). Results were consistent across subgroups and competing risk analysis.

Conclusion: In CKD patients aged ≥75 years, frailty was associated with progressive kidney disease, increased mortality, and healthcare utilization.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
虚弱表型对老年慢性肾脏病患者心肾风险和医疗保健利用率的影响。
导言:有关虚弱在老年慢性肾脏病(CKD)患者心肾风险中的作用的数据有限。我们研究了虚弱是否能预测这些患者的主要肾脏和心血管事件、医疗保健使用率和死亡率。方法 我们对估计肾小球滤过率(eGFR)稳定在 60 mL/min/1.73 m2 以下、年龄≥ 75 岁的患者进行了前瞻性队列研究。虚弱表型包括萎缩、活动少、疲惫、虚弱和迟钝,分为 0 至 5 分。主要的肾脏综合结果是 eGFR 下降≥ 25%,同时伴有 CKD 分期进展或开始透析。次要结果包括主要不良心血管事件(MACE)、急诊室就诊率、全因死亡率和住院率。我们使用带/不带竞争风险分析的多变量 Cox 模型探讨了虚弱对这些结果的影响。结果 在 203 名老年慢性肾脏病患者(平均年龄为 81.6 ± 5.0 岁,女性占 40.9%,糖尿病患者占 33.0%,体重指数为 24.9 ± 3.7 kg/m2)中,67.9% 的患者体质虚弱。在 3.47 年的时间里,38.9% 的人面临综合肾病后果,13.3% 的人面临 MACE,15.3% 的人面临死亡,半数以上的人使用了医疗保健服务。每虚弱一分,综合肾脏结果风险就会增加 28.0%(HR:1.28,95% CI:1.03-1.59),次要结果(住院[HR:1.24,95% CI:1.06-1.46]、意外急诊就诊[HR:1.20,[95% CI:1.03-1.39]和死亡率[HR:1.51,95% CI:1.06-2.16])也会显著增加,但 MACE [HR:1.43,95% CI:0.99-2.08]不会增加。不同亚组和竞争风险分析的结果一致。结论 在年龄≥75 岁的慢性肾脏病患者中,虚弱与肾脏疾病进展、死亡率和医疗保健使用率增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cardiorenal Medicine
Cardiorenal Medicine CARDIAC & CARDIOVASCULAR SYSTEMS-UROLOGY & NEPHROLOGY
CiteScore
5.40
自引率
2.60%
发文量
25
审稿时长
>12 weeks
期刊介绍: The journal ''Cardiorenal Medicine'' explores the mechanisms by which obesity and other metabolic abnormalities promote the pathogenesis and progression of heart and kidney disease (cardiorenal metabolic syndrome). It provides an interdisciplinary platform for the advancement of research and clinical practice, focussing on translational issues.
期刊最新文献
A New Era in the Management of Cardiorenal Syndrome: The Importance of Cardiorenal Units. Association of Liver Fibrosis Markers with Mortality Outcomes in Patients with Chronic Kidney Disease and Coronary Artery Disease: Insights from the NHANES 1999-2018 Data. EMCREG-International Multidisciplinary Consensus Panel on Management of Hyperkalemia in Chronic Kidney Disease (CKD) and Heart Failure. Cardiorenal disease and heart failure with preserved ejection fraction: Two sides of the same coin. Changes in Antigen Carbohydrate 125 in Patients Receiving Dapagliflozin Following an Admission for Acute Heart Failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1